{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T14:56:57Z","timestamp":1795100217845,"version":"4.10.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Joint Medical Science Research Project of Chongqing","award":["2021MSXM219"],"award-info":[{"award-number":["2021MSXM219"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-01947-z","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:27:17Z","timestamp":1739302037000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A novel defined risk signature of ferroptosis-related lncRNAs for predicting prognosis, immune infiltration, and chemotherapy response in multiple myeloma"],"prefix":"10.1007","volume":"16","author":[{"given":"Wei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizi","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107. https:\/\/doi.org\/10.1002\/ajh.26590.","journal-title":"Am J Hematol"},{"key":"1947_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003.","journal-title":"JAMA"},{"key":"1947_CR3","unstructured":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016 | Hematology | JAMA Oncology | JAMA Network. https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2681640. Accessed 7 Jun 2021"},{"key":"1947_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"key":"1947_CR5","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362. https:\/\/doi.org\/10.1182\/blood-2016-01-631200.","journal-title":"Blood"},{"key":"1947_CR6","doi-asserted-by":"publisher","first-page":"E2087","DOI":"10.3390\/ijms19072087","volume":"19","author":"W Willenbacher","year":"2018","unstructured":"Willenbacher W, Seeber A, Steiner N, et al. Towards molecular profiling in multiple myeloma: a literature review and early indications of its efficacy for informing treatment strategies. Int J Mol Sci. 2018;19:E2087. https:\/\/doi.org\/10.3390\/ijms19072087.","journal-title":"Int J Mol Sci"},{"key":"1947_CR7","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/cancers14081963","volume":"14","author":"I Saltarella","year":"2022","unstructured":"Saltarella I, Apollonio B, Lamanuzzi A, et al. The landscape of lncRNAs in multiple myeloma: implications in the \u201challmarks of cancer.\u201d Clin Perspect Ther Opport Cancers. 2022;14:1963. https:\/\/doi.org\/10.3390\/cancers14081963.","journal-title":"Clin Perspect Ther Opport Cancers"},{"key":"1947_CR8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/cam4.5135","volume":"12","author":"J Qin","year":"2023","unstructured":"Qin J, Ke B, Liu T, et al. Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: a systemic review and meta-analysis. Cancer Med. 2023;12:2199\u2013218. https:\/\/doi.org\/10.1002\/cam4.5135.","journal-title":"Cancer Med"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41392-022-01110-y","volume":"7","author":"F Peng","year":"2022","unstructured":"Peng F, Liao M, Qin R, et al. Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduct Target Ther. 2022;7:286. https:\/\/doi.org\/10.1038\/s41392-022-01110-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1947_CR10","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401\u201321. https:\/\/doi.org\/10.1016\/j.cell.2022.06.003.","journal-title":"Cell"},{"key":"1947_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12935-022-02742-4","volume":"22","author":"B Fu","year":"2022","unstructured":"Fu B, Shao R, Wang H, et al. Integrated assessment of the clinical and biological value of ferroptosis-related genes in multiple myeloma. Cancer Cell Int. 2022;22:326. https:\/\/doi.org\/10.1186\/s12935-022-02742-4.","journal-title":"Cancer Cell Int"},{"key":"1947_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgac080","author":"Q Su","year":"2022","unstructured":"Su Q, Li Q, Zhang W, et al. Integrative analysis of enrichment and prognostic value of ferroptosis-related genes and pathways in multiple myeloma. Carcinogenesis. 2022. https:\/\/doi.org\/10.1093\/carcin\/bgac080.","journal-title":"Carcinogenesis"},{"key":"1947_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12943-020-01157-x","volume":"19","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zhang S, Gong X, et al. The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Mol Cancer. 2020;19:39. https:\/\/doi.org\/10.1186\/s12943-020-01157-x.","journal-title":"Mol Cancer"},{"key":"1947_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1631\/jzus.B2200194","volume":"23","author":"L Qu","year":"2022","unstructured":"Qu L, He X, Tang Q, et al. Iron metabolism, ferroptosis, and lncRNA in cancer: knowns and unknowns. J Zhejiang Univ Sci B. 2022;23:844\u201362. https:\/\/doi.org\/10.1631\/jzus.B2200194.","journal-title":"J Zhejiang Univ Sci B"},{"key":"1947_CR15","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/0008-5472.CAN-17-3454","volume":"78","author":"C Mao","year":"2018","unstructured":"Mao C, Wang X, Liu Y, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Res. 2018;78:3484\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3454.","journal-title":"Cancer Res"},{"key":"1947_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00108-018-0529-8","volume":"60","author":"L Rasche","year":"2019","unstructured":"Rasche L, Weinhold N. Pathogenesis of multiple myeloma. Internist (Berl). 2019;60:3\u20139. https:\/\/doi.org\/10.1007\/s00108-018-0529-8.","journal-title":"Internist (Berl)"},{"key":"1947_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.948548","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Hu Y, Hamidi H, et al. Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. Front Oncol. 2022;12: 948548. https:\/\/doi.org\/10.3389\/fonc.2022.948548.","journal-title":"Front Oncol"},{"key":"1947_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13:110. https:\/\/doi.org\/10.1186\/s13045-020-00946-7.","journal-title":"J Hematol Oncol"},{"key":"1947_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270\u20134. https:\/\/doi.org\/10.1038\/s41586-019-1170-y.","journal-title":"Nature"},{"key":"1947_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.665173","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, Xu S-W, Zhu X-Y, et al. Identification and validation of a novel RNA-binding protein-related gene-based prognostic model for multiple myeloma. Front Genet. 2021;12: 665173. https:\/\/doi.org\/10.3389\/fgene.2021.665173.","journal-title":"Front Genet"},{"key":"1947_CR21","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/bioinformatics\/btn429","volume":"24","author":"H Jiang","year":"2008","unstructured":"Jiang H, Wong WH. SeqMap: mapping massive amount of oligonucleotides to the genome. Bioinformatics. 2008;24:2395\u20136. https:\/\/doi.org\/10.1093\/bioinformatics\/btn429.","journal-title":"Bioinformatics"},{"key":"1947_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baaa021","author":"N Zhou","year":"2020","unstructured":"Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database. 2020. https:\/\/doi.org\/10.1093\/database\/baaa021.","journal-title":"Database"},{"key":"1947_CR23","unstructured":"GSVA: gene set variation analysis for microarray and RNA-Seq data - PMC. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3618321\/. Accessed 27 Nov 2024"},{"key":"1947_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-021-00576-z","volume":"7","author":"Y Guo","year":"2021","unstructured":"Guo Y, Qu Z, Li D, et al. Identification of a prognostic ferroptosis-related lncRNA signature in the tumor microenvironment of lung adenocarcinoma. Cell Death Discov. 2021;7:1\u201311. https:\/\/doi.org\/10.1038\/s41420-021-00576-z.","journal-title":"Cell Death Discov"},{"key":"1947_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.778557","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Zhu Z, Li X, et al. The ferroptosis-related noncoding RNA signature as a novel prognostic biomarker in the tumor microenvironment, immunotherapy, and drug screening of gastric adenocarcinoma. Front Oncol. 2021;11: 778557. https:\/\/doi.org\/10.3389\/fonc.2021.778557.","journal-title":"Front Oncol"},{"key":"1947_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019.","journal-title":"Cell Rep"},{"key":"1947_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.922315","volume":"13","author":"X Ma","year":"2022","unstructured":"Ma X, Yu S, Zhao B, et al. Development and validation of a novel ferroptosis-related lncrna signature for predicting prognosis and the immune landscape features in uveal melanoma. Front Immunol. 2022;13: 922315. https:\/\/doi.org\/10.3389\/fimmu.2022.922315.","journal-title":"Front Immunol"},{"key":"1947_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an r package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9: e107468. https:\/\/doi.org\/10.1371\/journal.pone.0107468.","journal-title":"PLoS ONE"},{"key":"1947_CR29","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, et al. Genomics of drug sensitivity in cancer (GDSC): a RESOURCE FOR THERAPEUTIC BIOMARKER DISCOVERY IN CANCER CELLS. Nucleic Acids Res. 2013;41:D955-961. https:\/\/doi.org\/10.1093\/nar\/gks1111.","journal-title":"Nucleic Acids Res"},{"key":"1947_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fonc.2014.00385","volume":"4","author":"MK Callahan","year":"2014","unstructured":"Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol. 2014;4:385. https:\/\/doi.org\/10.3389\/fonc.2014.00385.","journal-title":"Front Oncol"},{"key":"1947_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"JP Friedmann Angeli","year":"2019","unstructured":"Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19:405\u201314. https:\/\/doi.org\/10.1038\/s41568-019-0149-1.","journal-title":"Nat Rev Cancer"},{"key":"1947_CR32","unstructured":"Construction and Validation of a 6-Ferroptosis Related Gene Signature for Prognosis and Immune Landscape Prediction in Melanoma - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35692844\/. Accessed 14 Feb 2023"},{"key":"1947_CR33","unstructured":"Multiple myeloma: the (r)evolution of current therapy and a glance into future - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33054076\/. Accessed 7 Jun 2024"},{"key":"1947_CR34","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.7150\/ijbs.66181","volume":"17","author":"J Huang","year":"2021","unstructured":"Huang J, Wang J, He H, et al. Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer. Int J Biol Sci. 2021;17:4493\u2013513. https:\/\/doi.org\/10.7150\/ijbs.66181.","journal-title":"Int J Biol Sci"},{"key":"1947_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16181","author":"Y Duan","year":"2024","unstructured":"Duan Y, Yan Y, Fu H, et al. SNHG15-mediated feedback loop interplays with HNRNPA1\/SLC7A11\/GPX4 pathway to promote gastric cancer progression. Cancer Sci. 2024. https:\/\/doi.org\/10.1111\/cas.16181.","journal-title":"Cancer Sci"},{"key":"1947_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1300","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi Z, Li Z, Jin B, et al. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. Clin Transl Med. 2023;13: e1300. https:\/\/doi.org\/10.1002\/ctm2.1300.","journal-title":"Clin Transl Med"},{"key":"1947_CR37","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12967-023-04640-3","volume":"21","author":"Y Ding","year":"2023","unstructured":"Ding Y, Huang Y, Zhang F, et al. LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p\/CREB1 axis. J Transl Med. 2023;21:854. https:\/\/doi.org\/10.1186\/s12967-023-04640-3.","journal-title":"J Transl Med"},{"key":"1947_CR38","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3389\/fonc.2020.00639","volume":"10","author":"Y Jiao","year":"2020","unstructured":"Jiao Y, Zhou J, Jin Y, et al. Long non-coding RNA TDRKH-AS1 promotes colorectal cancer cell proliferation and invasion through the \u03b2-catenin activated Wnt Signaling pathway. Front Oncol. 2020;10:639. https:\/\/doi.org\/10.3389\/fonc.2020.00639.","journal-title":"Front Oncol"},{"key":"1947_CR39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12935-022-02507-z","volume":"22","author":"X Bu","year":"2022","unstructured":"Bu X, Ma L, Liu S, et al. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int. 2022;22:95. https:\/\/doi.org\/10.1186\/s12935-022-02507-z.","journal-title":"Cancer Cell Int"},{"key":"1947_CR40","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41419-020-02820-3","volume":"11","author":"M Li","year":"2020","unstructured":"Li M, Ding X, Zhang Y, et al. Antisense oligonucleotides targeting lncRNA AC1040411 induces antitumor activity through Wnt2B\/\u03b2-catenin pathway in head and neck squamous cell carcinomas. Cell Death Dis. 2020;11:672. https:\/\/doi.org\/10.1038\/s41419-020-02820-3.","journal-title":"Cell Death Dis"},{"key":"1947_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031839","volume":"101","author":"Y Lin","year":"2022","unstructured":"Lin Y, Zhang Z, Li Y, et al. LncRNA DIRC1 is a novel prognostic biomarker and correlated with immune infiltrates in stomach adenocarcinoma. Medicine. 2022;101: e31839. https:\/\/doi.org\/10.1097\/MD.0000000000031839.","journal-title":"Medicine"},{"key":"1947_CR42","doi-asserted-by":"publisher","first-page":"8682","DOI":"10.26355\/eurrev_201812_16633","volume":"22","author":"Z Li","year":"2018","unstructured":"Li Z, Yang A-J, Wei F-M, et al. Significant association of DIRC1 overexpression with tumor progression and poor prognosis in gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22:8682\u20139. https:\/\/doi.org\/10.26355\/eurrev_201812_16633.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"1947_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcancer.2019.12.013","volume":"68","author":"H Yang","year":"2021","unstructured":"Yang H, Chen X, Li K, et al. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Semin Cancer Biol. 2021;68:105\u201322. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.013.","journal-title":"Semin Cancer Biol"},{"key":"1947_CR44","doi-asserted-by":"publisher","first-page":"189119","DOI":"10.1016\/j.bbcan.2024.189119","volume":"1879","author":"BA Alhasan","year":"2024","unstructured":"Alhasan BA, Morozov AV, Guzhova IV, Margulis BA. The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence. Biochimica et Biophysica Acta Rev Cancer. 2024;1879:189119. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189119.","journal-title":"Biochimica et Biophysica Acta Rev Cancer"},{"key":"1947_CR45","doi-asserted-by":"publisher","unstructured":"The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed\/refractory disease: Expert Review of Proteomics: Vol 19 , No 4\u20136 - Get Access. https:\/\/doi.org\/10.1080\/14789450.2022.2142564. Accessed 28 May 2024","DOI":"10.1080\/14789450.2022.2142564"},{"key":"1947_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2526-2","author":"W Yang","year":"2024","unstructured":"Yang W, Zhao Y, Yang Y. Dynamic RNA methylation modifications and their regulatory role in mammalian development and diseases. Sci China Life Sci. 2024. https:\/\/doi.org\/10.1007\/s11427-023-2526-2.","journal-title":"Sci China Life Sci"},{"key":"1947_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/ijo.2023.5605","volume":"64","author":"C Shao","year":"2023","unstructured":"Shao C, Han Y, Huang Y, et al. Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). Int J Oncol. 2023;64:17. https:\/\/doi.org\/10.3892\/ijo.2023.5605.","journal-title":"Int J Oncol"},{"key":"1947_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/MOH.0000000000000741","volume":"30","author":"W-J Wang","year":"2023","unstructured":"Wang W-J, Xu T-T, Bao J. N6-methyladenosine in hematological malignancies: a concise review. Curr Opin Hematol. 2023;30:4\u201313. https:\/\/doi.org\/10.1097\/MOH.0000000000000741.","journal-title":"Curr Opin Hematol"},{"key":"1947_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.571127","volume":"10","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yu C, Luo M, et al. Ferroptosis in cancer treatment: another way to Rome. Front Oncol. 2020;10: 571127. https:\/\/doi.org\/10.3389\/fonc.2020.571127.","journal-title":"Front Oncol"},{"key":"1947_CR50","unstructured":"Cancer immunotherapy: the beginning of the end of cancer?\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/27151159\/. Accessed 14 Feb 2023"},{"key":"1947_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.620596","author":"DE Joshua","year":"2021","unstructured":"Joshua DE, Vuckovic S, Favaloro J, et al. Treg and oligoclonal expansion of terminal effector CD8+ T cell as key players in multiple myeloma. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.620596.","journal-title":"Front Immunol"},{"key":"1947_CR52","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1126\/science.aaa1292","volume":"346","author":"Y Maeda","year":"2014","unstructured":"Maeda Y, Nishikawa H, Sugiyama D, et al. Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals. Science. 2014;346:1536\u201340. https:\/\/doi.org\/10.1126\/science.aaa1292.","journal-title":"Science"},{"key":"1947_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","volume":"22","author":"M Iglesias-Escudero","year":"2023","unstructured":"Iglesias-Escudero M, Arias-Gonz\u00e1lez N, Mart\u00ednez-C\u00e1ceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22:26. https:\/\/doi.org\/10.1186\/s12943-023-01714-0.","journal-title":"Mol Cancer"},{"key":"1947_CR54","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.3390\/jcm10194588","volume":"10","author":"C Hadjiaggelidou","year":"2021","unstructured":"Hadjiaggelidou C, Katodritou E. Regulatory T-cells and multiple myeloma: implications in tumor immune biology and treatment. J Clin Med. 2021;10:4588. https:\/\/doi.org\/10.3390\/jcm10194588.","journal-title":"J Clin Med"},{"key":"1947_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17474086.2024.2370552","volume":"17","author":"K \u017by\u0142ka","year":"2024","unstructured":"\u017by\u0142ka K, Kubicki T, Gil L, Dytfeld D. T-cell exhaustion in multiple myeloma. Expert Rev Hematol. 2024;17:295\u2013312. https:\/\/doi.org\/10.1080\/17474086.2024.2370552.","journal-title":"Expert Rev Hematol"},{"key":"1947_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/life14040461","volume":"14","author":"V Radhakrishnan","year":"2024","unstructured":"Radhakrishnan V, Golla U, Kudva AK. Role of immune cells and immunotherapy in multiple myeloma. Life. 2024;14:461. https:\/\/doi.org\/10.3390\/life14040461.","journal-title":"Life"},{"key":"1947_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109168","volume":"246","author":"E Roshandel","year":"2023","unstructured":"Roshandel E, Ghaffari-Nazari H, Mohammadian M, et al. NK cell therapy in relapsed refractory multiple myeloma. Clin Immunol. 2023;246: 109168. https:\/\/doi.org\/10.1016\/j.clim.2022.109168.","journal-title":"Clin Immunol"},{"key":"1947_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"key":"1947_CR59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/biom14050514","volume":"14","author":"J Han","year":"2024","unstructured":"Han J, Wang C, Yang H, et al. Novel insights into the links between n6-methyladenosine and regulated cell death in musculoskeletal diseases. Biomolecules. 2024;14:514. https:\/\/doi.org\/10.3390\/biom14050514.","journal-title":"Biomolecules"},{"key":"1947_CR60","doi-asserted-by":"publisher","first-page":"1383203","DOI":"10.3389\/fphar.2024.1383203","volume":"15","author":"MAU Din","year":"2024","unstructured":"Din MAU, Lin Y, Wang N, et al. Ferroptosis and the ubiquitin-proteasome system: exploring treatment targets in cancer. Front Pharmacol. 2024;15:1383203. https:\/\/doi.org\/10.3389\/fphar.2024.1383203.","journal-title":"Front Pharmacol"},{"key":"1947_CR61","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5374","author":"X Zhang","year":"2022","unstructured":"Zhang X, Meng T, Cui S, et al. Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review). Int J Oncol. 2022. https:\/\/doi.org\/10.3892\/ijo.2022.5374.","journal-title":"Int J Oncol"},{"key":"1947_CR62","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell HN, Stockwell BR, Zou W. Ironing out the role of ferroptosis in immunity. Immunity. 2024;57:941\u201356. https:\/\/doi.org\/10.1016\/j.immuni.2024.03.019.","journal-title":"Immunity"},{"key":"1947_CR63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ncrna.2023.11.005","volume":"9","author":"M Hashemi","year":"2024","unstructured":"Hashemi M, Daneii P, Zandieh MA, et al. Non-coding RNA-mediated N6-Methyladenosine (m6A) deposition: a pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response. Noncoding RNA Res. 2024;9:84\u2013104. https:\/\/doi.org\/10.1016\/j.ncrna.2023.11.005.","journal-title":"Noncoding RNA Res"},{"key":"1947_CR64","doi-asserted-by":"publisher","first-page":"13336","DOI":"10.3390\/ijms241713336","volume":"24","author":"X Zheng","year":"2023","unstructured":"Zheng X, Zhang C. The regulation of ferroptosis by noncoding RNAs. Int J Mol Sci. 2023;24:13336. https:\/\/doi.org\/10.3390\/ijms241713336.","journal-title":"Int J Mol Sci"},{"key":"1947_CR65","unstructured":"Exploring the regulatory role of lncRNA in cancer immunity\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/37637063\/. Accessed 5 Jun 2024"},{"key":"1947_CR66","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbrc.2016.08.124","volume":"478","author":"H Yuan","year":"2016","unstructured":"Yuan H, Li X, Zhang X, et al. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun. 2016;478:1338\u201343. https:\/\/doi.org\/10.1016\/j.bbrc.2016.08.124.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-01947-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-01947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:27:24Z","timestamp":1739302044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-01947-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-01947-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate: The study was reviewed and approved by internal review and ethics boards of the First Affiliated Hospital of Chongqing Medical University (approval No. K2023-235). The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All study participants or their legal guardians provided informed written consent about personal and medical data collection before study enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}